જગસનપાલ ફાર્માસ્યુટિકલ્સ શેર પ્રાઇસ

જગસનપાલ ફાર્માસ્યુટિકલ્સ ઇન્વેસ્ટમેન્ટ રેટિંગ

• માસ્ટર રેટિંગ:

• Jagsonpal Pharmaceuticals has an operating revenue of Rs. 209.99 Cr. on a trailing 12-month basis. An annual revenue de-growth of -10% needs improvement, Pre-tax margin of 14% is healthy, ROE of 11% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 10% and 26% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 4% from the pivot point (which is the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 53 which is a POOR score indicating inconsistency in earnings, a RS Rating of 67 which is FAIR indicating the recent price performance, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 43 indicates it belongs to a fair industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.